Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Dave & Buster's Enter's Earnings: A Preview

Dave & Buster's Enter (NASDAQ:PLAY) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Dave & Buster's Enter will report an earnings per share (EPS) of $0.61.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 25, 2022

Upgrades For Aris Water Solutions Inc (NYSE:ARIS), Capital One upgraded the previous rating of Equal-Weight to Overweight. The stock has a 52-week-high of $19.16 and a 52-week-low of $10.06. At the end of the last trading period, Aris Water Solutions closed at $18.55.

Benzinga

Preview: Brainstorm Cell's Earnings

Brainstorm Cell (NASDAQ:BCLI) is set to give its latest quarterly earnings report on Monday, 2022-03-28. Here's what investors need to know before the announcement. Analysts estimate that Brainstorm Cell will report an earnings per share (EPS) of $-0.20.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Looking Into Yumanity Therapeutics's Return On Capital Employed

Benzinga Pro data, Yumanity Therapeutics (NASDAQ:YMTX) reported Q4 sales of $762.00 thousand. Earnings fell to a loss of $10.41 million, resulting in a 4.57% decrease from last quarter.

Benzinga

ADMA Biologics's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, ADMA Biologics's (NASDAQ:ADMA) reported sales totaled $26.38 million. Despite a 6.0% increase in earnings, the company posted a loss of $16.65 million.

Benzinga

Looking Into PhaseBio Pharmaceuticals's Return On Capital Employed

Benzinga Pro data, PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported Q4 sales of $158.00 thousand. Earnings fell to a loss of $43.11 million, resulting in a 35.04% decrease from last quarter.

Benzinga

Looking Into TFF Pharmaceuticals's Return On Capital Employed

Benzinga Pro data, TFF Pharmaceuticals (NASDAQ:TFFP) reported Q4 sales of $12.00 thousand. Earnings fell to a loss of $10.05 million, resulting in a 15.8% decrease from last quarter.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Recap: DXP Enterprises Q4 Earnings

DXP Enterprises (NASDAQ:DXPE) reported its Q4 earnings results on Friday, March 25, 2022 at 09:20 AM. Here's what investors need to know about the announcement.

Benzinga

Looking Into Sigma Labs's Return On Capital Employed

According to Benzinga Pro data, during Q4, Sigma Labs (NASDAQ:SGLB) posted sales of $349.24 thousand. Earnings were up 3.76%, but Sigma Labs still reported an overall loss of $2.40 million.

Benzinga

Sight Sciences's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, Sight Sciences's (NASDAQ:SGHT) reported sales totaled $14.69 million. Despite a 7.18% increase in earnings, the company posted a loss of $15.94 million.

Benzinga

One Stop Systems's Return On Capital Employed Insights

One Stop Systems (NASDAQ:OSS) brought in sales totaling $17.78 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 139.38%, resulting in a loss of $386.24 thousand.

Benzinga

Aptevo Therapeutics Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data, during Q4, Aptevo Therapeutics (NASDAQ:APVO) posted sales of $3.67 million. Earnings were up 10.36%, but Aptevo Therapeutics still reported an overall loss of $6.27 million.

Benzinga

HOOKIPA Pharma's Return On Capital Employed Overview

Benzinga Pro data, HOOKIPA Pharma (NASDAQ:HOOK) reported Q4 sales of $3.90 million. Earnings fell to a loss of $21.23 million, resulting in a 5.96% decrease from last quarter.

Benzinga

AutoWeb Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data, during Q4, AutoWeb (NASDAQ:AUTO) posted sales of $17.80 million. Earnings were up 14.63%, but AutoWeb still reported an overall loss of $2.61 million.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Co-Diagnostics's Return On Capital Employed Insights

Pulled from Benzinga Pro data, Co-Diagnostics (NASDAQ:CODX) posted Q4 earnings of $7.50 million, an increase from Q3 of 34.66%. Sales dropped to $20.40 million, a 32.22% decrease between quarters.

Benzinga

Why Cyren Stock Is Trading Lower Today

CYREN Ltd (NASDAQ: CYRN) is trading lower Friday after the company reported worse-than-expected revenue results. Cyren said fourth-quarter revenue declined from $8.4 million to $7.4 million year-over-year, which came in below the $7.77 million estimate.

Benzinga

Here's Why Canaccord Is Bullish On This Cryptocurrency Mining Company

Canaccord Genuity analyst Joseph Vafi initiated coverage of HIVE Blockchain Technologies Ltd (NASDAQ:HIVE) with a Buy rating and a $2.80 price target, suggesting an upside of 27%. Digital assets, especially Bitcoin and Ethereum, successfully exited another test of their resiliency in the face of recent market volatility. Vafi expects miners to benefit if bitcoin prices…

Benzinga

YTRA: Yatra Online Files to IPO on India Exchanges

By Lisa Thompson NASDAQ:YTRA READ THE FULL YTRA RESEARCH REPORT

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Netflix Snaps Its Third Gaming Studio

Netflix Inc (NASDAQ:NFLX) acquired Boss Fight Entertainment, a mobile game developing studio, Venture Beat reports. The financial terms of the transaction remain undisclosed. Boss Fights joined Netflix's two other game studio acquisitions after Night School Studio and Next Games, Variety reports. Also Read: Needham Sees Netflix Losing Out To Amazon, Disney, Apple and Other Streaming Rivals…

Benzinga

Benzinga's Daily Brief On Trending Tickers For March 25, 2022: Tilray, Sundial, Bed Bath & Beyond, And More

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.

Benzinga

Why Cutera's Shares Are Soaring Today

The FDA has granted 510(k) clearance to Cutera Inc's (NASDAQ:CUTR) AviClear for acne. The Company notes that AviClear is the first and only energy-based device to receive this designation to treat mild, moderate, and severe acne. AviClear is a laser treatment that offers a safe, prescription-free solution for acne. In addition to reducing existing acne,…

Benzinga

(ASML) - Analyzing Asml Holding N.V. - New York Registry Shares's Short Interest

Asml Holding N.V. - New York Registry Shares's (NASDAQ:ASML) short percent of float has risen 10.34% since its last report. The company recently reported that it has 1.27 million shares sold short, which is 0.32% of all regular shares that are available for trading.

Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session

Benzinga

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

Benzinga

11 Industrials Stocks Moving In Friday's Pre-Market Session

1 … 780 781 782 783

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.